Marjolin's Ulcer in Chronic Burn Scar

1. Executive Overview: What is Marjolin’s Ulcer?

Marjolin’s Ulcer (ICD-10: C44.90) represents a rare, aggressive, and potentially lethal form of cutaneous malignancy that develops within chronic wounds, most notably old burn scars. Named after the French surgeon Jean-Nicolas Marjolin, who first described the phenomenon in 1828, this condition is essentially a squamous cell carcinoma (SCC) that arises from scarred, inflamed, or traumatized skin.

Unlike typical squamous cell carcinomas caused by ultraviolet radiation, Marjolin’s Ulcer is characterized by a significantly higher rate of metastasis and a more aggressive clinical course. It typically manifests decades after the initial injury, with the average latency period ranging from 20 to 35 years. Because the underlying scar tissue is often hypovascular and lacks normal sensory innervation, patients may remain asymptomatic until the lesion has reached an advanced stage, making early recognition and high clinical suspicion vital for successful outcomes.

2. Pathophysiology, Etiology, and Risk Factors

The transition from a stable, chronic scar to a malignant neoplasm is a complex process involving chronic inflammation, immune evasion, and genetic mutation.

The Mechanism of Malignant Transformation

The pathophysiology of Marjolin’s Ulcer is multifactorial. Several theories explain the malignant conversion:
* Chronic Irritation: Continuous cycles of tissue breakdown and attempted regeneration lead to DNA replication errors.
* Immune Privilege: Burn scars are often avascular and lack normal lymphatic drainage, creating an "immunologically privileged" site where malignant cells can evade detection by the body’s immune system.
* Genetic Instability: Chronic inflammation produces reactive oxygen species (ROS), which induce mutations in the p53 tumor suppressor gene, a common finding in these tumors.

Established Risk Factors

3. Signs, Symptoms, and Clinical Presentation

The clinical presentation of Marjolin’s Ulcer is often subtle, which frequently leads to a delay in diagnosis. It is imperative that clinicians maintain a high index of suspicion for any chronic scar that changes in character.

Classic Clinical Features

1. Induration: The margins of the scar become firm, raised, and "rolled."
2. Exophytic Growth: The lesion often appears as a cauliflower-like, fungating mass.
3. Chronic Discharge: A persistent, foul-smelling exudate or bleeding that does not respond to standard wound care.
4. Sensory Alteration: While the scar itself is often anesthetic, the development of pain is a red flag, suggesting deeper invasion into subcutaneous tissue, fascia, or bone.
5. Lymphadenopathy: Palpable regional lymph nodes should always be investigated, as Marjolin’s Ulcer has a high propensity for lymphatic spread.

4. Standard Diagnostic Evaluation & Workup

Early diagnosis is the single most important prognostic factor. A diagnostic delay of even a few months can result in an upgrade in tumor staging.

The Diagnostic Algorithm

• Physical Examination: A meticulous inspection of the scar, noting the presence of ulceration, friability, and secondary infection.
• Biopsy (The Gold Standard): A deep punch biopsy or wedge biopsy is mandatory. A superficial shave biopsy is often insufficient, as it may miss the invasive components of the tumor. Multiple biopsies from different areas of the ulcer are recommended to avoid sampling error.
• Imaging Modalities:
  • MRI: Essential for assessing the depth of invasion into the fascia, muscle, or underlying periosteum/bone.
  • CT/PET-CT: Used for systemic staging to rule out distant metastasis, especially in high-grade lesions.
  • Ultrasound: Useful for evaluating regional lymph node basins.

Differential Diagnosis

Clinicians must differentiate Marjolin’s Ulcer from:
* Chronic osteomyelitis (if bone is exposed).
* Fungal infections (e.g., blastomycosis).
* Pyoderma gangrenosum.
* Basal cell carcinoma.

5. Therapeutic Interventions

Treatment for Marjolin’s Ulcer is primarily surgical. Because these tumors are aggressive, wide local excision is the standard of care.

Surgical Management

• Wide Local Excision (WLE): The tumor must be excised with wide, clear margins—typically 1–2 cm, depending on the depth and grade of the lesion.
• Mohs Micrographic Surgery: In specific cases where tissue preservation is critical (e.g., facial lesions), Mohs surgery may be utilized to ensure complete clearance of tumor margins.
• Lymph Node Management: If regional nodes are clinically positive or PET-positive, a lymph node dissection (lymphadenectomy) is required. Sentinel lymph node biopsy (SLNB) remains controversial but is increasingly utilized in select patients.
• Reconstructive Surgery: Following excision, the defect is typically reconstructed using split-thickness skin grafts (STSG) or, in larger defects, rotational or free tissue flaps to provide stable, vascularized coverage.

Adjuvant Therapies

• Radiotherapy: Generally considered less effective for primary treatment but used as a palliative measure for unresectable tumors or in cases of positive margins where further surgery is not an option.
• Chemotherapy: Reserved for advanced, metastatic disease, though systemic response rates for SCC are generally modest.

6. Frequently Asked Questions (FAQ)

1. Is Marjolin’s Ulcer the same as a regular skin cancer?
No. While it is a type of Squamous Cell Carcinoma, it is significantly more aggressive than the SCC caused by sun exposure and has a much higher rate of metastasis.

2. How long after a burn does this usually happen?
The average latency period is roughly 30 years, but it can occur anywhere from 10 to 50+ years after the initial injury.

3. Is the condition painful?
Early stages are often painless due to nerve destruction in the scar. The onset of new pain is a warning sign that the cancer is invading deeper tissues.

4. Can this be prevented?
Yes. Regular dermatological screening for individuals with significant, long-standing burn scars is the best prevention. Any chronic non-healing wound should be biopsied.

5. What is the prognosis for Marjolin’s Ulcer?
Prognosis depends on the stage at diagnosis. Early excision leads to good outcomes, but delayed diagnosis significantly reduces the 5-year survival rate.

6. Does it only happen in burn scars?
While most common in burn scars, it can develop in any chronic wound, including osteomyelitis sinuses, venous stasis ulcers, or pressure sores.

7. Is surgery the only treatment?
Surgery is the gold standard. Radiation and chemotherapy are generally used as secondary or palliative options.

8. What tests will I need?
Expect a biopsy, followed by MRI or CT scans to check for deep tissue invasion or spread to lymph nodes.

9. Are all old scars dangerous?
No, but any scar that begins to ulcerate, bleed, or change in texture should be evaluated by a plastic surgeon immediately.

10. Can Marjolin’s Ulcer recur?
Yes. Even after successful excision, local recurrence is possible, necessitating long-term clinical surveillance and follow-up.

Disclaimer: This guide is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or qualified health provider with any questions regarding a medical condition.